S a n d r a P e k i c 1 and V e r a P o p o v i c -B r k i c 2
Pituitary adenomas are common benign monoclonal neoplasmsaccounting for 15% of intracranial neoplasms -that may be clinically silent or secrete anterior pituitary hormones such as prolactin, growth hormone (GH), adrenocorticotrophic hormone (ACTH) or, rarely, thyroid-stimulating hormone (TSH) or gonadotrophins. Radiological studies for other reasons using high-resolution computed tomography (CT) or magnetic resonance imaging (MRI) detect incidental pituitary adenomas in approximately 20% of asymptomatic patients. 1 The incidence of the various types of adenoma varies; 2 prolactinomas are the most common pituitary adenomas. Clinically non-functioning pituitary adenomas (NFPAs), which do not secrete hormones, often cause local mass symptoms and represent one-third of pituitary adenomas. GH-and ACTH-producing adenomas each account for 10-15% of pituitary adenomas, while TSH-producing adenomas are rare.
Pituitary adenomas are infrequent in childhood: fewer than 10% of pituitary adenomas are diagnosed before 20 years of age. 3 These adenomas can be either micro-or macroadenomas. The natural course of microadenomas is that a few tumours enlarge over a period of more than eight years.
Although several genes and signalling pathways have been identified as important factors in the development of pituitary tumours, our understanding of pituitary tumorigenesis remains incomplete and is the focus of current research. The reason for this is that current treatment modalities fail to completely control this disorder and prevent the associated morbidity and mortality. This article reviews the advances in our understanding of pituitary adenoma, especially in the field of pathogenesis of pituitary tumours, and the possibility of new therapeutic approaches.
Why Do Pituitary Microadenomas Fail to Grow?
Pituitary microadenomas, which have a diameter of less than 1cm, are exceedingly common, with a prevalence of 25% at autopsy and pituitary imaging. 4 Most microadenomas remain clinically occult and stable in size, without an increase in tumour cells and without local mass effects.
Recent studies have attempted to explain this cessation of growth, which would not be expected to occur in such tissue. It was thought that apoptosis might play a role in curtailing outgrowth, but this did not explain the stable size for several years. The lack of induction of vascular stroma was thought to be relevant, but again this was an insufficient explanation. The proliferative activity of microadenomas is low, which indicates that the growth of tumour cells is arrested.
The hypothesis is that after a certain number of cell divisions cells display a change in cell phenotype, i.e. they enter into a senescence-like state. 5 Currently, the likely factor in growth arrest in pituitary microadenomas is thought to be oncogene-induced cellular senescence. 6 The likelihood that the majority of pituitary adenomas are monoclonal in origin suggests that neoplasia arises either by oncogene activation or by inactivation of tumour-suppressor genes. 7 Upregulation of oncogenes plays a role in the pathogenesis of pituitary tumours, and oncogene-induced senescence results from the activation of powerful antiproliferative signalling networks (activated cell-cycle-progression inhibitors), which prevent the outgrowth of early neoplastic lesions driven by oncogenes. 8 One of the upregulated oncogenes is the pituitary tumour-transforming gene (Pttg), which facilitates cell-cycle progression, maintains chromosomal stability and mediates tumorigenesis. 9, 10 In a transgenic model, an overexpression of Pttg causes cell transformation and induces aneuploidy and tumorigenesis. 11 On the other hand, mice lacking Pttg have pituitary hypoplasia and the endocrine glands are senescent; these Pttg-null mice are protected from tumorigenesis. 12 Pttg abundance correlates with pituitary tumour invasiveness, recurrence and prognosis. 13 Furthermore, Pttg deletion selectively activates the pituitary pathway with decreased pituitary-cell proliferation, which may be a future target to restrain tumour growth.
Nowadays, it seems that the premature proliferative arrest of pituitary adenomas underlies their failure to enlarge and progress to malignancy.
Recent Advances in Understanding Somatotroph Tumorigenesis
The only oncogenes associated with GH-secreting adenomas are mutations of GNAS1, the gene encoding for the α subunit of the stimulatory G protein (Gs), i.e. the gsp oncogene. 14 screening is that the MEN1 carrier is periodically followed in order to recognise the tumour early. As for whether a young child at risk of mutation should undergo sequencing and then periodic monitoring, the consensus recommends periodic surveillance for tumours in known MEN1 carriers beginning at five years of age. 25 Research in these hereditary pituitary tumours is important since most investigators consider that the gene for a rare hereditary disorder also has important roles in common tumours of similar types. Menin pathways could be a potential drug target in the future.
Familial-isolated Pituitary Adenomas
FIPAs are isolated pituitary tumours that occur in families and are in a MEN-like state, in which GH is often oversecreted. Familial acromegaly has been described in the literature, and in an international study performed by Daly et al. 64 FIPA families were identified. 26, 27 Tumours in these families are macroadenomas and occur at a young age. Recently, genetic linkage studies pointed to a region of chromosome 11q13 that differs from the MEN1 gene region as the area for the idiopathic familial somatotrophinoma gene. 28 acromegaly. 29 Today, we know that FIPA is not limited to acromegaly, but includes all pituitary adenoma subtypes. [29] [30] [31] The 330-amino-acid AIP is a molecular chaperone protein involved in the functional maturation of aryl hydrocarbon receptor (AhR), the nuclear receptor for the environmental toxin dioxin. 32, 33 AIP has been shown to both increase and decrease the function of AhR. Loss of heterozygosity at the AIP locus implies germline mutations of AIP in FIPA families. 34 Not all of the families tested positive for this mutation. Those patients with AIP mutations were significantly younger than patients with FIPA without AIP mutations.
Immunostaining of normal pituitary with a monoclonal antibody revealed AIP staining in the cytoplasm of somatotroph and prolactin cells. Familial somatotroph tumours also stained positive for AIP, which is found in association with secretory granule. 34 Although an absence of AIP protein on immunostaining is likely with mutations, Leontiou and colleagues suggested that using AIP staining for screening for AIP mutations is not appropriate because AIP staining was observed in some tumours with AIP mutations. It is not clear how this molecular chaperone is involved in tumorigenesis.
Leontiou and colleagues overexpressed AIP in GH3 pituitary cell lines, which dramatically reduced cell proliferation, whereas mutant AIP lost this ability. 34 Thus, AIP suppresses cell proliferation. AIP mutations occur in 15% of familial pituitary adenoma syndromes. AIP was found to be a candidate [42] [43] [44] [45] Another interesting feature of NFPA is the lack of response to somatostatin analogues despite the presence of somatostatin receptors. What is even more puzzling is that these tumours do respond to somatostatin analogues in vitro (octreotide, paseriotide). 46 In an attempt to answer the question of why NFPAs do not respond to somatostatin analogues, Korbonits et al. observed in vitro significant inhibition of proliferative cell pathways (ERK) and upregulation of p27, an antiproliferative cellular pathway. 41 The lack of in vivo effects of somatostatin analogues is thought to be due to the induction of vascular endothelial growth factor (VEGF) by stimulation of somatostatin receptor 5 (SSTR5). 47 Thus, somatostatin receptor analogues, through activation of SSTR5, stimulate VEGF expression and cell proliferation. VEGF and VEGF receptors have been shown to be overexpressed in NFPA. 48 Another reason why somatostatin analogues are not effective may be due to increased seladin expression in NFPAs, as seladin is known to prevent apoptosis. 49 Furthermore, Zac1, a Zn-finger protein that regulates apoptosis, is downregulated in most pituitary adenomas. Somatostatin analogues increase Zac1 gene expression, and if Zac1 is downregulated, cells are unresponsive to somatostatin analogues. 50 As some NFPAs demonstrate an aggressive and invasive clinical course and somatostatin analogue therapy is ineffective, fortunately new treatments have recently become available. Temozolomide is a novel drug that was originally used in the treatment of cerebral gliomas and metastatic melanomas. It is an alkylating agent and inhibits angiogenesis in tumour tissue. 51 Temozolomide was first used in a patient with pituitary carcinoma in 2006 and subsequently in prolactinomas. [52] [53] [54] [55] Some patients responded to treatment and others did not, depending on the DNA methyltransferase (MGMT) expression. 56 
Conclusion
Small but significant advances in the field of pathogenesis of sporadic, familial and inherited pituitary tumours allow us to better understand the clinical presentation, and new pathophysiology brings novel therapeutic targets. I
